---
figid: PMC5343994__ijms-18-00461-g001
figtitle: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×: HIF-2a
  is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
  the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway'
organisms:
- NA
pmcid: PMC5343994
filename: ijms-18-00461-g001.jpg
figlink: /pmc/articles/PMC5343994/figure/ijms-18-00461-f001/
number: F1
caption: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×: HIF-2a
  is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
  the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway. Increased expression
  of transcription factor HIF-2α causes (blue arrows) higher levels of growth factors
  (GFs) VEGF, PDGF-β and TGF-α. Sorafenib and sunitinib block their receptors (in
  red TKI effects), and the intracellular Ras/Raf/MEK/ERK cascade (sorafenib) thereby
  inhibiting tumorigenesis and metastasis. Inhibition of GFs leads to a decrease in
  NO-production and reduced endothelial permeability, resulting in increased vasoconstriction,
  total peripheral resistance (TPR), and hypertension (red arrow).'
papertitle: Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment
  of Metastatic Renal Cell Carcinoma.
reftext: Caroline Randrup Hansen, et al. Int J Mol Sci. 2017 Feb;18(2):461.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.769654
figid_alias: PMC5343994__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC5343994__F1
ndex: 0ecf7dab-df2e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5343994__ijms-18-00461-g001.html
  '@type': Dataset
  description: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×:
    HIF-2a is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
    the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway. Increased expression
    of transcription factor HIF-2α causes (blue arrows) higher levels of growth factors
    (GFs) VEGF, PDGF-β and TGF-α. Sorafenib and sunitinib block their receptors (in
    red TKI effects), and the intracellular Ras/Raf/MEK/ERK cascade (sorafenib) thereby
    inhibiting tumorigenesis and metastasis. Inhibition of GFs leads to a decrease
    in NO-production and reduced endothelial permeability, resulting in increased
    vasoconstriction, total peripheral resistance (TPR), and hypertension (red arrow).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TPR
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - VHL
  - EPAS1
  - PDGFB
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EPHB2
  - MAPK1
  - MAPK3
  - TGFA
  - tpr
  - Mtor
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Vhl
  - Dsor1
  - Mtk
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Erk7
  - rl
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
